Monitor the company's next financial filings to assess the impact of this leadership change on financial reporting and strategy execution, particularly regarding their Phase 3 development program for TNX-103.
Price Chart
Executive Summary
Tenax Therapeutics appointed Thomas R. Staab, II as Chief Financial Officer effective May 11, 2026, replacing interim CFO Thomas A. McGauley. Staab will receive a $428,000 base salary and equity awards of 10,000 RSUs and options to purchase 450,000 shares as an inducement grant.
Key Facts
- Thomas R. Staab, II appointed as Chief Financial Officer effective May 11, 2026
- Staab replaces interim CFO Thomas A. McGauley who will continue in a consulting role through transition
- Staab's annual base salary is $428,000 with a target bonus of 45% of base salary
- Inducement equity awards include 10,000 restricted stock units and options to purchase 450,000 shares
- Equity awards were approved under Nasdaq Listing Rule 5635(c)(4) without shareholder approval
Financial Impact
Inducement equity awards of 10,000 RSUs and options to purchase 450,000 shares valued at current market price, plus $428,000 annual salary
Risk Factors
- Potential dilution from the issuance of new equity awards
- Risk associated with leadership transition during a critical phase of clinical development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-168521 |
| Document: d81080d8k.htm | 0001193125-26-168521 |
| Document: d81080dex102.htm | 0001193125-26-168521 |
| Document: d81080dex991.htm | 0001193125-26-168521 |
| Document: 0001193125-26-168521-index-headers.html | 0001193125-26-168521 |
| Document: 0001193125-26-168521-index.html | 0001193125-26-168521 |
| Document: 0001193125-26-168521.txt | 0001193125-26-168521 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.72 (+26.47%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.72 (+7.50%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.72 (−6.01%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.72 (−8.02%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.72 (−9.47%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.72 (−19.25%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.72 (−6.52%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.72 (+25.09%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.72 (+25.09%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.72 (−87.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers